DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Registration

By notice dated February 4, 2004 and published in the **Federal Register** on February 18, 2004, (69 FR 7656), Lipomed, Inc., One Broadway, Cambridge, Massachusetts 02142, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed below:

Drug	Schedule
Cathinone (1235)	1
Methaqualone (2565)	I
Gamma-Hydroxybutyric Acid	I
(2010).	_
Lysergic acid diethylamide (7315)	<u> </u>
Marihuana (7360)	!
Tetrahydrocannabinols (7370)	ļ
Mescaline (7381)	I
3, 4, 5-Trimethoxyamphetamine	I
(7390). 4-Bromo-2-5-	1
dimethoxyamphetamine (7391).	'
4-Methyl-2, 5-	1
dimethoxyamphetamine (7395).	'
2, 5-Dimethoxyamphetamine	1
(7396).	'
2, 5-Dimethoxy-4-	l i
ethylamphetamine (7399).	
3, 4-Methylenedioxyamphetamine	l i
(7400).	
3, 4-Methylenedioxy-N-	1
ethylamophetamine (7404).	
3, 4-	1
Methylenedioxymethamphetam-	
ine (7405).	
Psilocybin (7437)	1
Psilocyn (7438)	I
Acetyldihydrocodeine (9051)	1
Dihydromorphine (9145)	ļ ļ
Heroin (9200)	!
Tilidine (9750)	<u> </u>
Amphetamine (1100)	II II
Methamphetamine (1105)	
Amobarbital (2125)	
Secobarbital (2315) Phencyclidine (7471)	ii
Cocaine (9041)	ii II
Codeine (9050)	lii
Dihydrocodeine (9120)	l ii
Oxycodone (9143)	Lii
Hydromorphone (9150)	ii
Benzoylecgonine (9180)	ii
Hydrocodone (9193)	П
Lévorphanol (9220)	II
Methadone (9250)	II
Dextropropoxyphene (9273)	II
Morphine (9300)	П
Thebaine (9333)	II
Oxymorphone (9652)	II
Alfentanil (9737)	II
Fentanyl (9801)	II

The firm plans to import small reference standard quantities of finished commercial product from its sister company in Switzerland for sale to its customers for drug testing and pharmaceutical research and development.

No comments or objections have been received. DEA has considered the factors contained in Title 21, United States Code, Section 823(a) and determined that the registration of Lipomed, Inc. to import the listed controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Lipomed, Inc. to ensure that the company's registration is consistent with the public interest. This investigation included inspection and testing of the compnay's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to Section 1008(a) of the Controlled Substances Import and Export Act and in accordance with Title 21, Code of Federal Regulations, Section 1301.34, the above firm is granted registration as an importer of the basic class of controlled substance listed above.

Dated: June 28, 2004.

William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 04–18169 Filed 8–9–04; 8:45 am] BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By notice dated February 4, 2004, and published in the **Federal Register** on February 18, 2004, (69 FR 7657), Norac Corporation, 405 S. Motor Avenue P.O. Box 577, Azusa, California 91702, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of THC Tetrahydrocannabinols (7370), a basic class of controlled substance listed in Schedule I.

The firm plans to manufacture the controlled substances for formulation into pharmaceutical products.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Norac Corporation to manufacture the listed controlled substance is consistent with the public interest at this time. DEA has

investigated Norac Corporation to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to Title 21 United States Code 823 and Title 28 Code of Federal Regulations 0.100 and 0.104, the above firm is granted registration as a bulk manufacturer of the basic class(es) of controlled substance(s) listed.

Dated: June 28, 2004.

William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 04–18170 Filed 8–9–04; 8:45 am] **BILLING CODE 4410–09–M**

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances Notice of Registration

By Notice dated March 5, 2004, and published in the **Federal Register** on March 15, 2004, (69 FR 12180), Rhodes Technologies, 498 Washington Street, Coventry, Rhode Island 02816, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances:

Drug	Schedule
Tetrahydrocannabinols (7370) Methlphenidate (1724) Codeine (9050) Dihydrocodeine (9120) Oxycodone (9143) Hydromorphone (9150) Hydrocodone (9193) Thebaine (9333) Thebaine (9333) Noroxymorphone (9668) Fentanyl (9801)	

The company plans to produce bulk products for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Rhodes Technologies to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Rhodes Technologies to ensure that the company's registration is consistent with the public interest. The investigation had included inspection